ELISA/assay

Human Sclerostin, SOST ELISA Kit

MBS702938

48-Strip-Wells

565 USD

ELISA Kit

Human Sclerostin, SOST ELISA Kit

sclerosteosis

Human Sclerostin (SOST) ELISA Kit; VBCH; sclerostin; sclerosteosis

sclerostin; Sclerostin; sclerostin; sclerostin

SOST

SOST; SOST; CDD; VBCH; SOST1; UNQ2976/PRO7455/PRO7476

SOST_HUMAN

Human

213

This assay has high sensitivity and excellent specificity for detection of Human SOST. No significant cross-reactivity or interference between Human SOST and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Samples: Serum, plasma, tissue homogenates. Assay Type: Sandwich. Detection Range: 31.25 pg/ml-2000 pg/ml. Sensitivity: 7.8 pg/ml

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV% is less than 8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision (Precision between assays): CV% is less than 10%. Three samples of known concentration were tested in twenty assays to assess. Detection Wavelength: 450 nm. Sample Volume: 50-100ul. Protein Biological Process 1: Signaling Pathway. Protein Biological Process 3: Wnt signaling pathway

Principle of the Assay: This assay employs the quantitative sandwich enzyme immunoassay technique. Antibody specific for SOST has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any SOST present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for SOST is added to the wells. After washing, avidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of SOST bound in the initial step. The color development is stopped and the intensity of the color is measured.

13376846

NP_079513.1

NM_025237.2

Q9BQB4

24,031 Da

Disease Pathway (530764); RNF Mutants Show Enhanced WNT Signaling And Proliferation Pathway (1016209); Signal Transduction Pathway (477114); Signaling By WNT In Cancer Pathway (1016191); Signaling By Wnt Pathway (106510); TCF Dependent Signaling In Response To WNT Pathway (980475); Wnt Signaling Pathway (83061); Wnt Signaling Pathway (471); XAV939 Inhibits Tankyrase, Stabilizing AXIN Pathway (1016210); Misspliced LRP5 Mutants Have Enhanced Beta-catenin-dependent Signaling Pathway (1016208)

Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease. [provided by RefSeq, Jul 2008]

Function: Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.1 PublicationManual assertion based on experiment in:Ref.8

48-Strip-Wells

565 USD

96-Strip-Wells

810

5x96-Strip-Wells

2750

10x96-Strip-Wells

5150